Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	659.45B -38.6%
Revenue (ttm)	247.29B +8.2%
Net Income	15.62B -2.1%
EPS	2,371.01 -0.2%
Shares Out	6.56M
PE Ratio	42.43
Forward PE	21.87
Dividend	1,200.00 (1.17%)
Ex-Dividend Date	Sep 29, 2025

Volume	29,221
Average Volume	40,815
Open	99,200
Previous Close	100,600
Day's Range	98,200 - 103,400
52-Week Range	96,400 - 179,800
Beta	n/a
RSI	42.77
Earnings Date	Aug 13, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.